| Objective To explore the clinical value of salbutamol sulfate combined with fluticasone propionate in the treatment of pediatric bronchial asthma（PBA）. Methods A retrospective study was conducted on the clinical records of 120 children with PBA admitted to the Third Affiliated Hospital of Zhengzhou University from January 2020 to February 2021. Based on the different clinical interventions, the patients were divided into an experimental group of 61 cases and a control group of 59 cases. The control group was treated with nebulized inhalation of fluticasone propionate, while the experimental group received nebulized inhalation of salbutamol sulfate in addition to the treatment of control group. The lung function and inflammatory factors of the two groups were assessed before and after treatment, and the improvement of symptoms, length of hospital stay, fractional exhaled nitric oxide（FeNO）, and medication safety during treatment were also recorded. Results After treatment, the pulmonary function indicators, namely peak expiratory flow（PEF）, forced expiratory volume in the first second（FEV1）, and forced vital capacity（FVC）, showed improvements in both the experimental and control groups compared to the pre-treatment levels（P<0.05）. The degree of improvement for each indicator in the experimental group was significantly greater than that in the control group（P<0.05）. After the treatment, the Childhood Asthma Control Test（C-ACT） scores and FeNO levels in both groups improved compared to pre-treatment values（P<0.05）, with the experimental group showing significantly greater improvement（P<0.05）. Similarly, after treatment, the serum levels of tumor necrosis factor alpha（TNF-α）, interferon gamma（IFN-γ）, interleukin-4（IL-4）, and interleukin-10（IL-10） in both groups improved compared to before treatment（P<0.05）, and the improvements in the experimental group were superior to the control group（P<0.05）. The time for the resolution of clinical symptoms such as wheezing, coughing, and whistling rales, as well as the overall length of hospitalization, in the experimental group were notably shorter than those in the control group（t= 8.858, 7.032, 6.728, 5.770, all P<0.001）. There was no statistically significant disparity in the incidence of adverse reactions between the two groups（χ2=0.113, P=0.737）. Conclusion For PBA, the combination of salbutamol sulfate and fluticasone propionate is highly effective, which can alleviate the inflammatory reactions, improve lung function, accelerate the resolution of symptoms, and shorten the length of hospitalization, ensuring medication safety and reliability. |
